24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Opioid
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
15:00
Apple faces an uncomfortable choice: Raise prices or sacrifice its famously high margins
14:47
Teva’s transformation gains momentum as innovative drug sales rise 33%
14:34
Full list of Israeli high-tech layoffs in 2026
14:33
Nice to lay off 500 employees as it struggles to navigate the AI transition
More stories
Buzz
Most popular
Daily
Weekly
1
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
2
ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years
3
Israeli digital health company TailorMed acquired in $250 million deal
4
Perion to be acquired by India’s Affle for $420 million, marking a steep fall for a once-billion-dollar Israeli company
5
After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems
More news
Opioid
10 stories about Opioid
Why are investors so pleased about Teva's $4.35 billion opioid settlement?
27.07.22
|
Sophie Shulman
The settlement removes the cloud of uncertainty that hovered over Teva, which on the one hand prevented investors from placing trust in its stock, while on the other hand also prevented Teva management from making substantial moves
Teva reaches $4.35 billion settlement in U.S. opioid lawsuits, shares surge
27.07.22
|
Sophie Shulman and Reuters
Teva is set to pay state and local governments up to $3.7 billion in cash over 13 years plus a contribution of $1.2 billion worth of the opioid overdose reversal drug naloxone
Double trouble for Teva as NY State files charges on same day as DOJ
18.08.20
|
CTech
Governor Andrew M. Cuomo announced that the New York State Department of Financial Services has initiated administrative proceedings against Teva in connection with the Opioid Crisis
Teva Announces $23.25 Billion Opioid Abuse Settlement Agreement
22.10.19
|
Lilach Baumer
Teva announced on Monday a settlement with both Cuyahoga and Summit counties of Ohio, averting the trial scheduled for later that day, and an agreement in principle for a global settlement framework
Teva Makes $15 Billion Settlement Offer in U.S. Opioid Case, Report Says
16.10.19
|
Hezi Sternlicht
The Israeli drugmaker and several other drug distributors are set to face around 2,500 lawsuits related to the U.S. opioid abuse epidemic in just a week at a Cleveland, Ohio federal court
Judge Rejects Teva’s Request to Be Tried Separately in U.S. Opioid Case, Report Says
13.10.19
|
CTech
Teva made a last minute attempt to be tried separately in opioid abuse damages case set to be held on October 21 in federal court in Cleveland, Ohio
Court Approves One Teva Opioid Settlement, Many More to Come
25.06.19
|
Hezi Sternlicht
The settlement will see Teva will pay Oklahoma a one-time payment of $85 million to settle claims that it had played a role in exacerbating the U.S. opioid use epidemic there
Israel Leads OECD Countries on Opioid Use Increase, Says Report
19.05.19
|
Adrian Filut
Between 2011 and 2016, the availability of opioids in Israel grew by 125%, according to an OECD report published over the weekend
FDA Approves Teva’s Generic Nasal Spray for Opioid Overdose
21.04.19
|
Lilach Baumer
Commonly known as Narcan, the spray is considered a life-saving medication, and Teva’s drug is the first generic product approved that does not require medical training to use
Bidder Contests Teva Sale of Jerusalem Facility
31.03.19
|
Amitai Gazit and Lilach Baumer
Earlier this month, Teva agreed to sell the land tenure rights of its two Jerusalem factories, set to close by the end of 2019, for a combined $77 million